Thermo Fisher Scientific raised its 2026 revenue and adjusted EPS guidance after reporting Q1 2026 revenue growth and improved outlook. Chairman and CEO Marc Casper said full-year 2026 revenue is now expected between $47.3 billion and $48.1 billion, with guidance for organic growth and adjusted EPS both increased versus the prior range. In the quarter ended March 28, Thermo Fisher reported $11.01 billion in revenue, up 6% year over year, and cited strength in bioproduction within its life sciences solutions segment. The company also pointed to muted demand for instruments from academic and government customers in the U.S. and China. The update is notable for the broader biotech ecosystem because Thermo Fisher remains a key supplier for reagents, instruments, and contract biomanufacturing—guidance shifts can quickly propagate to downstream lab spending and workflow planning.